Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings.
Amita GuptaXin SunSonya KrishnanMitch M MatogaSamuel PierreKatherine McIntireLucy KoechSharlaa FaesenCissy KityoSufia S DadabhaiKogieleum NaidooWadzanai P SamanekaJavier R LamaValdilea G VelosoVidya MaveUmesh LallooDeborah LangatEvelyn HoggGregory P BissonJohnstone KumwendaMina C Hosseinipournull nullPublished in: Open forum infectious diseases (2022)
Empiric TB treatment offered no longer-term advantage over IPT in our population with advanced immunosuppression initiating ART. High IPT adherence significantly lowered death and TB incidence through 96 weeks, emphasizing the benefit of ART plus IPT initiation and completion, in persons with advanced HIV living in high TB-burden, resource-limited settings.
Keyphrases
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected
- mycobacterium tuberculosis
- hiv aids
- hiv positive
- hiv infected patients
- hepatitis c virus
- risk factors
- gestational age
- type diabetes
- cardiovascular disease
- preterm infants
- pulmonary tuberculosis
- metabolic syndrome
- combination therapy
- adipose tissue
- glycemic control
- replacement therapy